OncoMatch/Clinical Trials/NCT06754085
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Is NCT06754085 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Florastamin[18F] for prostate cancer.
Treatment: Florastamin[18F] — In this study, 18F-Florastamin PET/CT will be performed in patients with suspected recurrence of prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: definitive therapy
subsequent definitive therapy
Cannot have received: androgen deprivation therapy
Exception: if previously taking ADT, it should have been discontinued at least 16 weeks prior to study drug administration
If previously taking ADT, it should have been discontinued at least 16 weeks prior to study drug administration
Lab requirements
Blood counts
Platelet count >50 × 10^9/L
Kidney function
Urea/urea nitrogen and creatinine <1.5 times upper limits of normal
Liver function
AST and ALT <2.5 times upper limits of normal
Platelet count>50 × 10^9/L Urea/urea nitrogen and creatinine<1.5 times upper limits of normal AST and ALT<2.5 times upper limits of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify